Types of Peptides: Complete Classification Guide (2026)

Overview

Peptides are short chains of amino acids — typically between 2 and 50 residues — that serve as signaling molecules throughout the body. While thousands of peptides exist in nature, the subset attracting research and clinical interest can be organized into functional categories based on their primary biological activity. This classification is not rigid: many peptides act through multiple pathways and could reasonably appear in more than one category. GHK-Cu, for example, functions as both a healing peptide and a cosmetic compound, while LL-37 serves antimicrobial and immune-modulatory roles simultaneously. The categories below represent the most useful organizational framework for understanding how different peptides relate to one another, what conditions they target, and where they stand in terms of clinical evidence. Regulatory status varies widely across these categories — some contain FDA-approved medications, while others consist entirely of investigational or research-stage compounds. This guide is strictly educational and does not constitute a recommendation to use any compound. All peptide therapy decisions should involve a qualified healthcare provider.

Growth Hormone Secretagogues

Growth hormone secretagogues (GHS) are peptides that stimulate the pituitary gland to release endogenous growth hormone (GH). Unlike exogenous GH administration, secretagogues work through the body's natural feedback mechanisms, producing pulsatile GH release that more closely mimics physiological patterns. This category operates through two primary receptor pathways: growth hormone-releasing hormone (GHRH) receptor agonists, which directly stimulate GH synthesis and release, and ghrelin/growth hormone secretagogue receptor (GHS-R) agonists, which amplify GH pulses and may also stimulate appetite. Some practitioners combine peptides from both pathways — for example, pairing a GHRH analog like CJC-1295 with a GHS-R agonist like Ipamorelin — to produce synergistic GH elevation while maintaining physiological pulsatility. Clinical applications under investigation include age-related GH decline, body composition optimization, recovery from injury, and improving sleep quality through enhanced slow-wave sleep associated with GH pulses. Tesamorelin is the only GHRH analog with FDA approval (for HIV-associated lipodystrophy), while MK-677 is an oral non-peptide secretagogue that has been studied in clinical trials.

• Sermorelin — A GHRH analog (first 29 amino acids of GHRH) that stimulates natural GH release; previously FDA-approved for GH deficiency diagnosis
• Ipamorelin — A selective GHS-R agonist with minimal effect on cortisol and prolactin; frequently paired with CJC-1295 in clinical practice
• CJC-1295 — A modified GHRH analog with extended half-life; available with or without Drug Affinity Complex (DAC)
• CJC-1295 DAC — CJC-1295 conjugated with Drug Affinity Complex for sustained GH elevation over days rather than hours
• GHRP-2 — A potent GHS-R agonist that strongly stimulates GH release but also increases cortisol and prolactin levels
• GHRP-6 — A first-generation GHS-R agonist known for significant appetite stimulation via ghrelin pathway activation
• Hexarelin — The most potent synthetic GHS-R agonist; produces strong GH release but is subject to rapid desensitization with repeated use
• Tesamorelin — FDA-approved GHRH analog (Egrifta) for reducing visceral adipose tissue in HIV-associated lipodystrophy
• MK-677 (Ibutamoren) — An oral, non-peptide GHS-R agonist studied in clinical trials for muscle wasting and GH deficiency; not FDA-approved

Healing & Recovery Peptides

Healing and recovery peptides promote tissue repair through mechanisms including angiogenesis (new blood vessel formation), modulation of inflammatory pathways, extracellular matrix remodeling, and stem cell recruitment. These compounds have attracted significant interest in sports medicine and orthopedic research for their potential to accelerate recovery from injuries to tendons, ligaments, muscles, and the gastrointestinal tract. The evidence base varies considerably within this category. BPC-157, a pentadecapeptide derived from human gastric juice, has an extensive preclinical literature demonstrating accelerated healing across multiple tissue types in animal models, but lacks published human clinical trial data. TB-500, the synthetic version of an active fragment of Thymosin Beta-4, has been studied for its role in cell migration and wound healing. GHK-Cu is unique in that it has both healing and cosmetic applications, functioning as a copper-binding tripeptide that activates tissue remodeling genes. KPV and LL-37 bridge healing and antimicrobial categories, with anti-inflammatory properties that support mucosal healing in addition to their direct antimicrobial activity.

• BPC-157 — A 15-amino acid peptide derived from gastric juice; extensively studied in animals for tendon, ligament, muscle, and gut healing
• TB-500 — Synthetic fragment of Thymosin Beta-4 that promotes cell migration, angiogenesis, and tissue repair; studied primarily in veterinary and preclinical settings
• Thymosin Beta-4 — The full-length 43-amino acid protein from which TB-500 is derived; involved in actin regulation, wound healing, and anti-inflammatory signaling
• GHK-Cu — A copper-binding tripeptide that activates tissue remodeling genes, stimulates collagen synthesis, and promotes wound healing
• KPV — A tripeptide (Lys-Pro-Val) derived from alpha-MSH with potent anti-inflammatory properties; studied for gut mucosal healing and inflammatory skin conditions
• LL-37 — The only human cathelicidin antimicrobial peptide; promotes wound healing through angiogenesis and immune modulation in addition to direct microbial killing

Weight Loss Peptides & GLP-1 Agonists

Weight loss peptides represent the most commercially significant and clinically validated category in peptide therapeutics. The dominant compounds are GLP-1 (glucagon-like peptide-1) receptor agonists and related incretin mimetics, which reduce appetite, slow gastric emptying, and improve glycemic control. Semaglutide and tirzepatide have become among the best-selling pharmaceuticals globally, with combined annual revenue exceeding $30 billion. These drugs produce clinically meaningful weight loss of 15-24% of body weight in large randomized controlled trials — results that have fundamentally changed the obesity treatment landscape. Beyond approved GLP-1 agonists, this category includes next-generation investigational compounds like retatrutide (a triple GIP/GLP-1/glucagon receptor agonist) and orforglipron (the first oral non-peptide GLP-1 agonist in late-stage development). It also includes older or less-validated compounds like AOD-9604 (a growth hormone fragment) and 5-Amino-1MQ (an NNMT inhibitor), which have weaker evidence but are available through research suppliers. The evidence gap between FDA-approved medications and research compounds in this category is enormous.

• Semaglutide (Wegovy/Ozempic) — FDA-approved GLP-1 agonist; 15-17% mean weight loss in STEP trials; once-weekly subcutaneous injection
• Tirzepatide (Zepbound/Mounjaro) — FDA-approved dual GIP/GLP-1 agonist; up to 22.5% weight loss in SURMOUNT-1; once-weekly injection
• Liraglutide (Saxenda) — Earlier FDA-approved GLP-1 agonist; approximately 8% mean weight loss; requires daily injection
• Retatrutide — Investigational triple GIP/GLP-1/glucagon agonist; 24.2% weight loss in phase 2 trials; phase 3 ongoing
• Survodutide — Investigational dual GLP-1/glucagon agonist being developed for obesity and metabolic liver disease
• AOD-9604 — Synthetic fragment of human growth hormone (amino acids 177-191); reached phase 2 for obesity but development stalled
• 5-Amino-1MQ — NNMT inhibitor with preclinical data showing fat reduction in animal models; no human clinical trials
• Orforglipron — Investigational oral non-peptide GLP-1 agonist in phase 3 trials; could eliminate the need for injections

Nootropic & Neuroprotective Peptides

Nootropic and neuroprotective peptides target cognitive function, neuroplasticity, and neuronal survival through diverse mechanisms. This category spans a wide range of clinical validation: from compounds with decades of clinical use in specific countries to purely preclinical research molecules. Several of the most-studied nootropic peptides originated in Russian neuroscience research programs. Selank and Semax are both synthetic analogs of endogenous peptides — Selank is derived from the immunomodulatory peptide tuftsin, while Semax is based on an ACTH fragment — and both are approved as medications in Russia for anxiety and cognitive enhancement, respectively. Their mechanisms involve modulation of neurotransmitter systems (serotonin, dopamine, BDNF) and gene expression in the brain. At the more experimental end, Dihexa is an angiotensin IV analog that has shown extraordinary potency in animal models of cognitive enhancement, with activity at picomolar concentrations, but has no human safety data. P21 (a CNTF-derived peptide) promotes neurogenesis in animal models. This category requires particular caution because the blood-brain barrier complicates peptide delivery, and cognitive outcomes are difficult to measure objectively.

• Selank — Synthetic tuftsin analog approved in Russia as an anxiolytic; modulates serotonin, dopamine, and BDNF; studied for anxiety and cognitive function
• Semax — Synthetic ACTH(4-10) analog approved in Russia; promotes BDNF expression and neuroprotection; studied for stroke recovery and cognitive enhancement
• Dihexa — Angiotensin IV analog with potent procognitive effects in animal models at picomolar doses; no human safety or efficacy data
• P21 — A small peptide derived from ciliary neurotrophic factor (CNTF) that promotes neurogenesis and reduces neuroinflammation in animal models of neurodegeneration
• Cerebrolysin — A mixture of low-molecular-weight neuropeptides derived from porcine brain tissue; approved in several countries for stroke and dementia; studied in clinical trials
• PE-22-28 — A synthetic peptide that acts as a positive allosteric modulator of sigma-1 receptors; studied in animal models for antidepressant and neuroprotective effects
• Pinealon — A tripeptide (Glu-Asp-Arg) studied for neuroprotective and geroprotective properties; part of the Khavinson peptide bioregulator research program
• Cortagen — A tetrapeptide bioregulator studied for its effects on cerebral cortex gene expression and neuroprotection in animal models

Antimicrobial Peptides

Antimicrobial peptides (AMPs) are a critical component of innate immunity across virtually all living organisms. In the human body, AMPs serve as a first line of defense against bacteria, fungi, viruses, and parasites — killing pathogens through mechanisms that are fundamentally different from conventional antibiotics. Most AMPs disrupt microbial membranes through electrostatic interactions with negatively charged bacterial surfaces, making it difficult for pathogens to develop resistance through single-point mutations. This resistance-resistant mechanism has made AMPs a major focus of pharmaceutical research as antibiotic resistance becomes an increasingly urgent global health threat. Beyond direct antimicrobial activity, many AMPs also function as immune modulators — recruiting immune cells, promoting wound healing, and regulating inflammatory responses. LL-37 and KPV exemplify this dual functionality, combining pathogen-killing capability with tissue-protective anti-inflammatory effects. Thymosin Alpha-1 operates primarily through immune system modulation rather than direct antimicrobial action, enhancing the body's ability to fight infections by activating dendritic cells and natural killer cells.

• LL-37 — The only human cathelicidin; disrupts bacterial membranes and biofilms; also promotes wound healing and modulates immune responses
• KPV — Anti-inflammatory tripeptide with antimicrobial properties; studied for its effects on gut mucosal inflammation and pathogenic bacteria
• Thymosin Alpha-1 (Zadaxin) — Approved in over 30 countries as an immune modulator; enhances T-cell function and has been used as adjunct therapy in hepatitis and immunodeficiency

Cosmetic & Skin Peptides

Cosmetic peptides represent one of the most commercially developed peptide categories, with applications in anti-aging skincare, wound care, and dermatology. Unlike most other categories in this guide, cosmetic peptides are primarily formulated for topical application rather than injection, which simplifies their regulatory pathway and consumer accessibility. The mechanisms of action in this category center on collagen stimulation, extracellular matrix remodeling, neuromuscular signal modulation, and melanin regulation. GHK-Cu is the most extensively researched cosmetic peptide, with studies demonstrating its ability to activate over 4,000 genes involved in tissue remodeling and repair. Signal peptides like Matrixyl (palmitoyl pentapeptide-4) stimulate fibroblast production of collagen and other matrix proteins. Neurotransmitter-inhibiting peptides like Argireline and SNAP-8 work by a mechanism loosely analogous to botulinum toxin — they interfere with the SNARE complex involved in muscle contraction, reducing the appearance of expression lines without injection. Clinical evidence for cosmetic peptides is generally moderate, based on smaller dermatological studies rather than large-scale randomized trials.

• GHK-Cu — Copper tripeptide that activates tissue remodeling genes, stimulates collagen and glycosaminoglycan synthesis; used in topical serums and injectable protocols
• GHK — The parent tripeptide (without copper) that naturally occurs in plasma and declines with age; serves as a signaling molecule for tissue repair
• Argireline (Acetyl Hexapeptide-3) — A neurotransmitter-inhibiting peptide that reduces muscle contraction intensity; marketed as a topical alternative to botulinum toxin for expression lines
• Matrixyl (Palmitoyl Pentapeptide-4) — A signal peptide that stimulates collagen I, III, and fibronectin synthesis in dermal fibroblasts; widely used in anti-aging formulations
• SNAP-8 (Acetyl Octapeptide-3) — An extended version of Argireline with enhanced SNARE complex modulation; designed for deeper expression line reduction

Sexual Health Peptides

Sexual health peptides act primarily through central nervous system pathways to modulate sexual arousal and desire, distinguishing them mechanistically from phosphodiesterase-5 inhibitors (such as sildenafil) that work through peripheral vascular mechanisms. PT-141 (bremelanotide) is the most clinically developed compound in this category — it is FDA-approved under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides approved specifically for a sexual health indication. PT-141 activates melanocortin-4 receptors (MC4R) in the hypothalamus, stimulating neural pathways associated with sexual arousal independently of hormonal or vascular mechanisms. Kisspeptin-10 has emerged as a research compound of interest because the kisspeptin system is a master regulator of the hypothalamic-pituitary-gonadal axis, governing the release of gonadotropin-releasing hormone (GnRH). Melanotan II, while primarily associated with skin tanning through melanocyte stimulation, also activates melanocortin receptors involved in sexual arousal — though its broader receptor activity profile carries a wider range of side effects.

• PT-141 (Bremelanotide/Vyleesi) — FDA-approved MC4R agonist for hypoactive sexual desire disorder in premenopausal women; acts through central nervous system pathways
• Kisspeptin-10 — A hypothalamic neuropeptide that regulates GnRH release and the reproductive axis; studied in clinical research for modulating sexual arousal and reproductive function
• Melanotan II — A non-selective melanocortin receptor agonist originally developed for skin tanning; produces sexual arousal as a secondary effect through MC4R activation; not FDA-approved

Longevity & Mitochondrial Peptides

Longevity and mitochondrial peptides target fundamental aging mechanisms including telomere maintenance, mitochondrial dysfunction, oxidative stress, and cellular senescence. This is among the most scientifically intriguing but also the most speculative peptide categories — the complexity of aging biology means that even promising mechanistic data may not translate to meaningful human lifespan or healthspan extension. Epithalon (also spelled Epitalon) is a synthetic tetrapeptide based on the pineal gland's epithalamin that has been studied for its ability to activate telomerase, the enzyme that maintains protective telomere caps on chromosomes. Animal studies have shown lifespan extension in several model organisms, though human longevity data is nonexistent. The mitochondrial-derived peptides (MDPs) — MOTS-c, Humanin, and SS-31 — represent a newer frontier. These peptides are encoded within the mitochondrial genome and appear to function as retrograde signals from mitochondria to the nucleus, regulating metabolic homeostasis and stress resistance. NAD+ precursors, while not peptides in the traditional sense, are frequently discussed alongside longevity peptides because NAD+ decline is a hallmark of aging and its restoration has broad metabolic implications.

• Epithalon (Epitalon) — Synthetic tetrapeptide (Ala-Glu-Asp-Gly) that activates telomerase; studied in animal models for lifespan extension and pineal gland function
• MOTS-c — Mitochondrial-derived peptide that activates AMPK and enhances metabolic homeostasis; studied for exercise-mimetic and insulin-sensitizing effects in animals
• Humanin — Mitochondrial-derived peptide with cytoprotective and anti-apoptotic properties; studied for neuroprotection and metabolic regulation; declines with age
• SS-31 (Elamipretide) — Targets cardiolipin in the inner mitochondrial membrane to restore electron transport chain efficiency; in clinical trials for mitochondrial myopathy and heart failure
• NAD+ precursors (NMN, NR) — Not classical peptides but frequently grouped with longevity compounds; restore cellular NAD+ levels that decline with age; oral supplements widely available

Sleep & Recovery Peptides

Sleep peptides modulate the neurochemical pathways that regulate sleep architecture, circadian rhythm, and recovery during rest. This is a small but distinct category, as relatively few peptides have been studied specifically for sleep-related applications. DSIP (Delta Sleep-Inducing Peptide) is the most recognized compound in this category — it was first isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep and was named for its ability to promote delta-wave (slow-wave) sleep in animal models. The exact mechanism of DSIP remains incompletely understood, but it appears to modulate multiple systems including GABAergic transmission, serotonin metabolism, and the hypothalamic-pituitary-adrenal axis. Human studies from the 1980s and 1990s showed mixed results for insomnia, with some trials reporting improved sleep quality and reduced sleep latency while others found no significant effect. Selank, while primarily categorized as a nootropic, has documented anxiolytic properties that may secondarily improve sleep quality by reducing the anxiety and hyperarousal that contribute to insomnia. Neither compound is FDA-approved for sleep disorders.

• DSIP (Delta Sleep-Inducing Peptide) — A nonapeptide that modulates sleep architecture and promotes slow-wave sleep; studied in limited human trials for insomnia with mixed results
• Selank — Primarily a nootropic and anxiolytic peptide; its anxiety-reducing effects may improve sleep quality in individuals whose insomnia is driven by stress or hyperarousal

Immune Peptides

Immune peptides modulate the innate and adaptive immune systems through mechanisms including T-cell maturation, dendritic cell activation, cytokine regulation, and direct pathogen defense. This category overlaps significantly with antimicrobial and healing peptides, reflecting the deeply interconnected nature of immune function, infection control, and tissue repair. Thymosin Alpha-1 is the most clinically established immune peptide — it is approved in over 30 countries (though not in the United States) for hepatitis B and C treatment and as an immune adjuvant, and has been used in cancer immunotherapy protocols. It functions primarily by enhancing T-cell differentiation and maturation, improving the immune system's ability to recognize and respond to pathogens and abnormal cells. Thymosin Beta-4, while classified primarily as a healing peptide, also plays critical roles in immune cell migration and inflammation resolution. KPV and LL-37, discussed in both the antimicrobial and healing categories, contribute to immune defense through complementary mechanisms — direct pathogen killing, immune cell recruitment, and modulation of inflammatory cascades. The immune peptide category is particularly relevant in the context of immunodeficiency, chronic infections, and adjunctive cancer therapy.

• Thymosin Alpha-1 (Zadaxin) — Approved in 30+ countries for hepatitis and immune deficiency; enhances T-cell maturation, dendritic cell function, and natural killer cell activity
• Thymosin Beta-4 — Involved in immune cell migration, inflammation resolution, and tissue repair; the parent protein of the TB-500 healing peptide
• KPV — Anti-inflammatory tripeptide that modulates NF-kB signaling and cytokine production; studied for autoimmune and inflammatory conditions
• LL-37 — Human cathelicidin with direct antimicrobial activity and immune-modulatory functions including chemotaxis and immune cell activation

Understanding Peptide Overlap Between Categories

One of the most important concepts in peptide classification is that many compounds belong to multiple categories simultaneously. This is not a weakness of the taxonomy — it reflects the biological reality that peptides often act through pleiotropic mechanisms affecting multiple physiological systems. GHK-Cu appears in both healing and cosmetic categories because the same tissue-remodeling properties that accelerate wound healing also produce anti-aging skin benefits. LL-37 functions as an antimicrobial, immune modulator, and healing peptide because innate immune defense, infection control, and tissue repair evolved as interconnected systems. Thymosin Beta-4 bridges immune and healing categories for similar reasons. When evaluating any peptide, it is more useful to understand its mechanism of action than to assign it a single category. The functional overlap also means that a peptide chosen for one purpose may produce effects in other domains — both beneficial and potentially unwanted. A comprehensive understanding of a peptide's full activity profile is essential for informed decision-making, and underscores why all peptide therapy decisions should be made in consultation with a qualified healthcare provider who understands these complexities.

References

1. Classification of bioactive peptides (2017) — PubMed
2. Growth hormone secretagogues: history, mechanism of action, and clinical development (2000) — PubMed
3. GLP-1 receptor agonists in obesity management (2021) — PubMed
4. Antimicrobial peptides: an emerging category of therapeutic agents (2016) — PubMed
5. Cosmeceutical peptides in dermatology (2019) — PubMed